Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 457.07Cr 395.87Cr 369.02Cr 339.4Cr 640.73Cr 43TCr 647.89Cr 4.34TCr 1.7TCr 22TCr 1.72TCr 1.68TCr 72TCr P/E 2026 *
10.4x
P/E 2027 * 9.43x
Enterprise Value 462.52Cr 400.59Cr 373.42Cr 343.45Cr 648.37Cr 44TCr 655.62Cr 4.39TCr 1.72TCr 22TCr 1.74TCr 1.7TCr 73TCr EV / Sales 2026 *
3.48x
EV / Sales 2027 * 3.06x
Free-Float
97.99%
Yield 2026 *
-
Yield 2027 * -
1 week+5.27%
1 month+20.78%
3 months+60.36%
6 months+29.91%
Current year+20.90%
1 week 1,160
Extreme 1160
1,264
1 month 975.5
Extreme 975.5
1,264
3 years 554.83
Extreme 554.83
2,020
5 years 335
Extreme 335
2,020
Change 5-day change 1-year change 3-year change Capi.($)
+1.56%+5.27%+49.52%-20.18% 457.07Cr
+4.86%-3.32%+52.73%+160.26% 1,04300Cr
+1.04%-2.99%+50.87%+52.38% 62TCr
+0.98%-6.49%+24.00%+66.66% 44TCr
+0.34%+3.62%+47.30%+38.27% 36TCr
+0.82%-1.07%+35.78%+39.59% 29TCr
-0.56%-5.85%+8.34%+10.01% 25TCr
+4.57%+5.21%+35.91%+67.64% 22TCr
+0.76%-9.93%+2.95%-45.38% 20TCr
-2.58%-0.73%+17.16%+67.46% 16TCr
Average +0.77%-3.81%+32.46%+43.67% 39.88TCr
Weighted average by Cap. +0.82%-3.79%+38.46%+76.06%

Financials

2026 *2027 *
Net sales 132.72Cr 114.95Cr 107.15Cr 99Cr 186.05Cr 13TCr 188.13Cr 1.26TCr 494.21Cr 6.31TCr 498.47Cr 487.48Cr 21TCr 136.2Cr 117.96Cr 109.96Cr 101.14Cr 190.93Cr 13TCr 193.06Cr 1.29TCr 507.17Cr 6.48TCr 511.54Cr 500.26Cr 21TCr
Net income 47Cr 40Cr 38Cr 35Cr 65Cr 4.44TCr 66Cr 443.06Cr 173.9Cr 2.22TCr 175.4Cr 171.53Cr 7.36TCr 50Cr 44Cr 41Cr 37Cr 70Cr 4.78TCr 71Cr 476.77Cr 187.13Cr 2.39TCr 188.74Cr 184.58Cr 7.92TCr
Net Debt 5.45Cr 4.72Cr 4.4Cr 4.05Cr 7.64Cr 518.22Cr 7.73Cr 52Cr 20Cr 259.29Cr 20Cr 20Cr 858.76Cr -40Cr -35Cr -33Cr -30Cr -57Cr -3.84TCr -57Cr -382.72Cr -150.21Cr -1.92TCr -151.51Cr -148.17Cr -6.36TCr
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
38.73USD
Average target price
49.00USD
Spread / Average Target
+26.52%

Quarterly revenue - Rate of surprise